Institution
University of Colorado Denver
Education•Denver, Colorado, United States•
About: University of Colorado Denver is a education organization based out in Denver, Colorado, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 27444 authors who have published 57213 publications receiving 2539937 citations. The organization is also known as: CU Denver & UCD.
Topics: Population, Poison control, Health care, Diabetes mellitus, Cancer
Papers published on a yearly basis
Papers
More filters
••
Washington University in St. Louis1, University of Utah2, University of Illinois at Chicago3, Baylor College of Medicine4, University of Pennsylvania5, University of Iowa6, University of Colorado Denver7, Alfred I. duPont Hospital for Children8, Boston Children's Hospital9, Oregon Health & Science University10, Concord Hospital11, University of Kansas12, Wake Forest University13
TL;DR: This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHD.
560 citations
••
Washington University in St. Louis1, University of Verona2, University of Oslo3, Boston Children's Hospital4, Medical University of Vienna5, University of Aberdeen6, University of Virginia7, University of Colorado Denver8, Charles University in Prague9, University of Manitoba10, Free University of Berlin11
TL;DR: This consensus report recommends strategies that include pharmacological treatment, allergen and trigger avoidance and asthma education that are recommended for clinical practice in Europe as well as in North America.
Abstract: Asthma is the leading chronic disease among children in most industrialized countries. However, the evidence base on specific aspects of pediatric asthma, including therapeutic strategies, is limited and no recent international guidelines have focused exclusively on pediatric asthma. As a result, the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology nominated expert teams to find a consensus to serve as a guideline for clinical practice in Europe as well as in North America. This consensus report recommends strategies that include pharmacological treatment, allergen and trigger avoidance and asthma education. The report is part of the PRACTALL initiative, which is endorsed by both academies.
560 citations
••
University of Michigan1, National Institutes of Health2, University of California, Irvine3, Saint Louis University4, Virginia Commonwealth University5, University of Colorado Denver6, University of Southern California7, University of Texas Southwestern Medical Center8, University of Connecticut9, Harvard University10, University of Washington11, United States Department of Veterans Affairs12
TL;DR: It was found that maintenance peginterferon did not reduce the incidence of HCC in the HALT-C cohort, and baseline clinical and laboratory features predicted risk for HCC.
559 citations
••
TL;DR: The role of complement is tested using a mouse model and it is shown that respiratory disease is significantly reduced in the absence of complement even though viral load is unchanged, suggesting that inhibition of complement signaling might be an effective treatment option following coronavirus infection.
Abstract: Acute respiratory distress syndrome (ARDS) is immune-driven pathologies that are observed in severe cases of severe acute respiratory syndrome coronavirus (SARS-CoV) infection. SARS-CoV emerged in 2002 to 2003 and led to a global outbreak of SARS. As with the outcome of human infection, intranasal infection of C57BL/6J mice with mouse-adapted SARS-CoV results in high-titer virus replication within the lung, induction of inflammatory cytokines and chemokines, and immune cell infiltration within the lung. Using this model, we investigated the role of the complement system during SARS-CoV infection. We observed activation of the complement cascade in the lung as early as day 1 following SARS-CoV infection. To test whether this activation contributed to protective or pathologic outcomes, we utilized mice deficient in C3 (C3–/–), the central component of the complement system. Relative to C57BL/6J control mice, SARS-CoV-infected C3–/– mice exhibited significantly less weight loss and less respiratory dysfunction despite equivalent viral loads in the lung. Significantly fewer neutrophils and inflammatory monocytes were present in the lungs of C3–/– mice than in C56BL/6J controls, and subsequent studies revealed reduced lung pathology and lower cytokine and chemokine levels in both the lungs and the sera of C3–/– mice than in controls. These studies identify the complement system as an important host mediator of SARS-CoV-induced disease and suggest that complement activation regulates a systemic proinflammatory response to SARS-CoV infection. Furthermore, these data suggest that SARS-CoV-mediated disease is largely immune driven and that inhibiting complement signaling after SARS-CoV infection might function as an effective immune therapeutic. IMPORTANCE The complement system is a critical part of host defense to many bacterial, viral, and fungal infections. It works alongside pattern recognition receptors to stimulate host defense systems in advance of activation of the adaptive immune response. In this study, we directly test the role of complement in SARS-CoV pathogenesis using a mouse model and show that respiratory disease is significantly reduced in the absence of complement even though viral load is unchanged. Complement-deficient mice have reduced neutrophilia in their lungs and reduced systemic inflammation, consistent with the observation that SARS-CoV pathogenesis is an immune-driven disease. These data suggest that inhibition of complement signaling might be an effective treatment option following coronavirus infection.
559 citations
••
Janeway Children's Health and Rehabilitation Centre1, Cincinnati Children's Hospital Medical Center2, Baylor College of Medicine3, Yale University4, University of Colorado Denver5, Boston Children's Hospital6, University of Cincinnati7, University of Toronto8, Hospital for Sick Children9, Ottawa Hospital Research Institute10, Memorial University of Newfoundland11, Emory University12, University of California, San Diego13
TL;DR: This guideline is designed to guide screening and clinical care of children with nonalcoholic fatty liver disease and is a management challenge for general pediatric practitioners, subspecialists and for health systems.
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease that occurs in the setting of insulin resistance and increased adiposity. It has rapidly evolved into the most common liver disease seen in the pediatric population and is a management challenge for general pediatric practitioners, subspecialists, and for health systems. In this guideline, the expert committee on NAFLD reviewed and summarized the available literature, formulating recommendations to guide screening and clinical care of children with NAFLD.
559 citations
Authors
Showing all 27683 results
Name | H-index | Papers | Citations |
---|---|---|---|
Matthew Meyerson | 194 | 553 | 243726 |
Charles A. Dinarello | 190 | 1058 | 139668 |
Gad Getz | 189 | 520 | 247560 |
Gordon B. Mills | 187 | 1273 | 186451 |
Jasvinder A. Singh | 176 | 2382 | 223370 |
David Haussler | 172 | 488 | 224960 |
Donald G. Truhlar | 165 | 1518 | 157965 |
Charles M. Perou | 156 | 573 | 202951 |
David Cella | 156 | 1258 | 106402 |
Bruce D. Walker | 155 | 779 | 86020 |
Marco A. Marra | 153 | 620 | 184684 |
Thomas E. Starzl | 150 | 1625 | 91704 |
Marc Humbert | 149 | 1184 | 100577 |
Rajesh Kumar | 149 | 4439 | 140830 |
Martin J. Blaser | 147 | 820 | 104104 |